|
Synonyms: ABBV-101 | Compound 1 [US20240109877]
Compound class:
Synthetic organic
Comment: Omtebrutideg is the INN for a Bruton tyrosine kinase PROTAC degrader. It is proposed for antineoplastic effects. The structure indicates that it is designed to engage the cereblon (CRBN) E3 ubiquitin ligase. Available evidence suggests that omtebrutideg is likely the INN for Abbvie's lead BTK PROTAC ABBV-101 [2-3]. Targeted protein degradation is intended as a strategy to overcome BTK inhibitor resistance in B cell malignancies.
|
|
|||||||||||||||||||||||||||||||||||
| No information available. |
Summary of Clinical Use ![]() |
| ABBV-101 was progressed as a clinical candidate. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT05753501 | Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies | Phase 1 Interventional | AbbVie | ||